Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

115.08 -1.13 (-0.97%)
Streaming Delayed Price Updated: 11:53 AM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
News headline image
Inflation's Shadow Lengthens: September CPI Ignites Fed Caution Amidst Government Shutdown
Washington D.C., October 10, 2025 – The financial markets are bracing for impact as the September 2025 Consumer Price Index (CPI) report looms, a critical piece of economic data that promises to shine... 
Via MarketMinute
Topics Bonds Economy World Trade
News headline image
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments ↗
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies. 
Via Benzinga
News headline image
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Zoetis (NYSE:ZTS) Signals Robust Health with Q4 2025 Dividend Declaration, Bolstering Investor Confidence in Animal Health Sector
Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This... 
Via MarketMinute
Topics Economy
News headline image
Zoetis (NYSE:ZTS) Declares $0.50 Q4 2025 Dividend, Signaling Robust Animal Health Market
NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This... 
Via MarketMinute
News headline image
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Economy Intellectual Property Retirement
News headline image
Behind the Scenes of Merck & Co's Latest Options Trends ↗
 
Via Benzinga
News headline image
5 Healthcare Plays Powering the Sector’s Big Comeback ↗
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest. 
Via MarketBeat
News headline image
Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
From Merck Sharp & Dohme
Via Business Wire
News headline image
MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Merck, Doctors Reject Proposal To Break Up Combined MMR Vaccine ↗
Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizations and weaken immune response. 
Via Benzinga
News headline image
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment ↗
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug. 
Via Investor's Business Daily
News headline image
Merck Completes Acquisition of Verona Pharma
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
From Merck Sharp & Dohme
Via Business Wire
News headline image
1 Monster Stock in the Making to Buy and Hold ↗
This biotech company was relatively unknown a few years ago. 
Via The Motley Fool
News headline image
Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Markets ↗
S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech. 
Via Benzinga
Topics Artificial Intelligence Stocks
News headline image
Merck & Co's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
U.S. Jobs Report Stalled Amidst Federal Shutdown: A Critical Information Vacuum for Markets and Policymakers
Washington D.C., October 2, 2025 – As a federal government shutdown extends into its second day, the highly anticipated U.S. Jobs Report, typically released on the first Friday of each month, has been... 
Via MarketMinute
Topics Bonds Economy
News headline image
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap ↗
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount. 
Via Benzinga
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%. 
Via The Motley Fool
Topics Stocks
News headline image
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Nanobiotix Stock Soars on Breakthrough Esophageal Cancer Data, Igniting Biotech Hopes
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a... 
Via MarketMinute
News headline image
Wall Street Holds Firm Despite Shutdown and Weak Jobs Data ↗
Stocks shrugged off Washington’s chaos as hopes for Fed rate cuts and strong corporate news kept investors in a buying mood. 
Via Chartmill
Topics Economy
News headline image
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years ↗
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs. 
Via Benzinga
Topics Government
News headline image
Why Merck (MRK) Stock Is Up Today
Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 7.7% in the afternoon session after the Trump administration announced a new program to sell drugs directly to consumers. 
Via StockStory
Topics Artificial Intelligence Government
News headline image
Wednesday's session: top gainers and losers in the S&P500 index ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
In today's session, there are S&P500 stocks with remarkable trading volume. ↗
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session. 
Via Chartmill
News headline image
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? ↗
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga
News headline image
Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.